We recently compiled a list of the 13 Best Pharma Dividend Stocks To Buy In 2024. In this article, we are going to take a ...

Stay updated on the latest developments in the GLP-1 drug class, including a new generic entering the market, weight loss results, FDA decisions & cost issues.

The pharmaceutical industry in 2024 faced a relatively quiet year, with deal volumes similar to 2023 but lower deal values, ...

From public campaigns featuring Cyndi Lauper to ads with dinosaurs, MM+M compiles the best public marketing campaigns from ...

Ziltivekimab is under clinical development by Novo Nordisk and currently in Phase III for Myocardial Infarction.

As weight-loss drugs have exploded in popularity this past year, part of the craze has been members of the public wondering which celebrities are on Ozempic.

Nordic firms have outperformed those from the rest of Europe over the past decade. In all four countries, listed ...

Liraglutide is under development for the treatment of obesity, ileal pouch-anal anastomosis and Alzheimer's disease. It was also under development for non-alcoholic steatohepatitis, psoriatic ...

A big rally in defense stocks, deal-fueled gains in banks and a surge in Siemens Energy AG shares were among the main ...

Eli Lilly and Novo Nordisk are likely to introduce its popular injectable drugs semaglutide and tirzepatide in India in 2025.

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...

Following rapid (and pricey) expansion efforts from Novo and Lilly, plus recent shortage updates at the FDA, “positive ...